Cognition Therapeutics
Price & Volume
Stats
See moreOpen | $1.12 |
Previous Close | $1.12 |
Day Range | $1.09-$1.17 |
52W Range | $0.22-$3.83 |
Market Cap | $91.8M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$0.47 |
News
See moreYahoo Finance • 3 months ago
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Yahoo Finance • 3 months ago
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Yahoo Finance • 3 months ago
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
Yahoo Finance • 3 months ago
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
About
CEO | Ms. Lisa Ricciardi |
Address | 2500 Westchester Ave., Purchase, NY, United States, 10577 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 25 |
